686342-80-3

Basic information

• Product Name: 5-Amino-4-iodo-2-methyl-benzoic acid methyl ester
• Synonyms: 5-Amino-4-iodo-2-methyl-benzoic acid methyl ester;methyl 5-amino-4-iodo-2-methylbenzoate
• CAS NO: 686342-80-3
• Molecular Formula: C₉H₁₀INO₂
• Molecular Weight: 291.08567
• Mol File: 686342-80-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-Amino-4-iodo-2-methyl-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-4-iodo-2-methyl-benzoic acid methyl ester(686342-80-3)
• EPA Substance Registry System: 5-Amino-4-iodo-2-methyl-benzoic acid methyl ester(686342-80-3)

Safety Data

• Hazardous Substances Data: 686342-80-3(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 857246-07-2 C₈H₈ClNO 
• 64688-68-2 2-methyl-5-nitrobenzoyl chloride 
• 77324-87-9 methyl 2-methyl-5-nitrobenzoate 
• 1975-52-6 5-nitro-o-toluic acid 
• 18595-12-5 methyl 5-amino-2-methylbenzoate 

Downstream Products

• 618881-38-2 methyl [3-amino-4-(hept-1-ynyl)-6-methyl]benzoate 
• 1186038-00-5 C₂₁H₁₆ClN₃O₂ 
• 1186038-01-6 5-(3-chlorophenylamino)-9-methylbenzo[c][2,6]naphthyridine-8-carboxylic acid 
• 782499-32-5 methyl [3-hydroxymethyl-2-(1-pentyl)-1-(2-phenylethyl)-5-methyl]indole-6-carboxylate 
• 618881-41-7 methyl [3-formyl-2-pentyl-1-(2-phenylethyl)-5-methyl]indole-6-carboxylate 

Relevant articles and documents

TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X11 and X22 are independently C or N, provided that zero or one of X11 and X22 is N; Ring A represented by the structure is: or; and Q, R11, R22, R33, R44, R66, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

NMR evaluation of interactions between substituted-indole and PDZ1 domain of PSD-95

We synthesized small organic molecules designed as PDZ ligands. These indole-based compounds were evaluated for their interaction with the PDZ1 domain of the post-synaptic density 95 (PSD-95) protein. Three molecules were found to interact with the targeted PDZ protein by NMR. One of them showed chemical shift perturbations closely related to the natural ligands.

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[ c ][2,6]naphthyridine-8- carboxylic Acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the Treatment of Cancer

Herein we chronicle the discovery of CX-4945 (25n), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clinical trials for cancer. CK2 has long been considered a prime cancer drug target because of the roles of deregulated and overexpressed CK2 in cancer-promoting prosurvival and antiapoptotic pathways. These biological properties as well as the suitability of CK2s small ATP binding site for the design of selective inhibitors, led us to fashion novel therapeutic agents for cancer. The optimization leading to 25n (Ki = 0.38 nM) was guided by molecular modeling, suggesting a strong binding of 25n resulting from a combination of hydrophobic interactions, an ionic bridge with Lys68, and hydrogen bonding with the hinge region. 25n was found to be highly selective, orally bioavailable across species (20-51%) and efficacious in xenograft models. The discovery of 25n will allow the therapeutic targeting of CK2 in humans for the first time.

PROTEIN KINASE MODULATORS

The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.

Small molecule inhibition of a PDZ-domain interaction

Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general formula The invention also includes combinatorial libraries, arrays and methods for screening and studying proteins using such compounds. Compounds of the invention have produced apoptosis in certain cell lines that overexpress the Dishevelled protein (Dvl); inhibiting Wnt signaling.

A selective irreversible inhibitor targeting a PDZ protein interaction domain

Irreversible inhibitors of proteases have proven themselves useful tools for determining which proteases are active under given conditions in tissues or cells and for studying the functional role that a protease plays in physiological processes. The application of such techniques to the study of the activity and function of protein-protein interactions has been hindered by the lack of guiding principles for the mechanistic design of irreversible inhibitors targeting the "active site" of a protein interaction. We report herein the first example of a mechanism-based irreversible inhibitor of a protein interaction that has been specifically targeted to one member of the PDZ family of protein interaction domains: the second PDZ domain of the membrane-associated guanylate kinase MAGI3. This inhibitor was designed using rationally directed computational evaluation to take advantage of a conserved histidine in the PDZ domain by introducing an ionizable group that will be held in close proximity to that nucleophile during binding. The novel compound exhibits all of the characteristics of an irreversible inhibitor of the interaction of the tumor suppressor PTEN with MAGI3 in in vitro models. In cells, the inhibitor can be shown to release PTEN from sequestration by MAGI3 and consequently upregulate the PKB signaling pathway. Copyright